Digging Deeper: Advancements in Visualization of Inhibitory Synapses in Neurodegenerative Disorders

Int J Mol Sci. 2021 Nov 18;22(22):12470. doi: 10.3390/ijms222212470.

Abstract

Recent research has provided strong evidence that neurodegeneration may develop from an imbalance between synaptic structural components in the brain. Lately, inhibitory synapses communicating via the neurotransmitters GABA or glycine have come to the center of attention. Increasing evidence suggests that imbalance in the structural composition of inhibitory synapses affect deeply the ability of neurons to communicate effectively over synaptic connections. Progressive failure of synaptic plasticity and memory are thus hallmarks of neurodegenerative diseases. In order to prove that structural changes at synapses contribute to neurodegeneration, we need to visualize single-molecule interactions at synaptic sites in an exact spatial and time frame. This visualization has been restricted in terms of spatial and temporal resolution. New developments in electron microscopy and super-resolution microscopy have improved spatial and time resolution tremendously, opening up numerous possibilities. Here we critically review current and recently developed methods for high-resolution visualization of inhibitory synapses in the context of neurodegenerative diseases. We present advantages, strengths, weaknesses, and current limitations for selected methods in research, as well as present a future perspective. A range of new options has become available that will soon help understand the involvement of inhibitory synapses in neurodegenerative disorders.

Keywords: Alzheimer’s disease; EM; SIM; STED; STORM; inhibitory synapse; neurodegeneration; synaptic plasticity.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / diagnostic imaging*
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology
  • Amyotrophic Lateral Sclerosis / diagnostic imaging
  • Amyotrophic Lateral Sclerosis / drug therapy
  • Amyotrophic Lateral Sclerosis / metabolism
  • Amyotrophic Lateral Sclerosis / pathology
  • Animals
  • Brain / diagnostic imaging*
  • Brain / drug effects
  • Brain / metabolism
  • Brain / pathology
  • Humans
  • Huntington Disease / diagnostic imaging
  • Huntington Disease / drug therapy
  • Huntington Disease / metabolism
  • Huntington Disease / pathology
  • Levodopa / therapeutic use
  • Memantine / therapeutic use
  • Microscopy, Electron / methods
  • Multiple Sclerosis / diagnostic imaging
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / metabolism
  • Multiple Sclerosis / pathology
  • Neuronal Plasticity / drug effects
  • Neurons / drug effects
  • Neurons / metabolism
  • Neurons / ultrastructure*
  • Neuroprotective Agents / therapeutic use*
  • Neurotransmitter Agents / metabolism
  • Parkinson Disease / diagnostic imaging*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology
  • Synapses / drug effects
  • Synapses / metabolism
  • Synapses / ultrastructure*
  • Synaptic Transmission / drug effects
  • Tetrabenazine / therapeutic use

Substances

  • Neuroprotective Agents
  • Neurotransmitter Agents
  • Levodopa
  • Memantine
  • Tetrabenazine